AI-generated summary
The authors reviewed 37 preclinical and clinical studies of photobiomodulation in aging and age-related conditions. They report improvements in several memory and cognitive measures in animal models and in some human groups, with mixed results for recognition memory and anxiety. The authors state that wavelengths and application protocols varied widely and call for standardized protocols.
- Studies included
- 37
- Who or what was studied
- Healthy aged humans, people with Alzheimer disease or mild cognitive impairment, Parkinson disease models, and aged animal models
- Wavelengths
- 800, 810, 1064 nm
- Limits stated in the abstract
- The abstract notes highly variable intensities and application days across studies, mixed results for recognition memory and anxiety, and the need for standardized protocols.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Aging is a multifactorial biological process that may be associated with cognitive decline. Photobiomodulation (PBM) is a non-pharmacological therapy that shows promising results in the treatment or prevention of age-related cognitive impairments. The aim of this review is to compile the preclinical and clinical evidence of the effect of PBM during aging in healthy and pathological conditions, including behavioral analysis and neuropsychological assessment, as well as brain-related modifications. 37 studies were identified by searching in PubMed, Scopus, and PsycInfo databases. Most studies use wavelengths of 800, 810, or 1064 nm but intensity and days of application were highly variable. In animal studies, it has been shown improvements in spatial memory, episodic-like memory, social memory, while different results have been found in recognition memory. Locomotor activity improved in Parkinson disease models. In healthy aged humans, it has been outlined improvements in working memory, cognitive inhibition, and lexical/semantic access, while general cognition was mainly enhanced on Alzheimer disease or mild cognitive impairment. Anxiety assessment is scarce and shows mixed results. As for brain activity, results outline promising effects of PBM in reversing metabolic alterations and enhancing mitochondrial function, as evidenced by restored CCO activity and ATP levels. Additionally, PBM demonstrated neuroprotective, anti-inflammatory, immunomodulatory and hemodynamic effects. The findings suggest that PBM holds promise as a non-invasive intervention for enhancing cognitive function, and in the modulation of brain functional reorganization. It is necessary to develop standardized protocols for the correct, beneficial, and homogeneous use of PBM.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1064 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Systematic review, Mild cognitive impairment, Adenosine triphosphate, Cytochrome c oxidase, Cognitive decline, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.